A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Elaina Gartner, MD
Seagen Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford Cancer Center
Stanford, California, United States
- Rocky Mountain Cancer Centers - Midtown
Denver, Colorado, United States
- Karmanos Cancer Institute / Wayne State University
Detroit, Michigan, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Unc Lineberger Comprehensive Cancer Center / University of North Carolina
Chapel Hill, North Carolina, United States
- Miriam Hospital, the
Providence, Rhode Island, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Seattle Cancer Care Alliance / University of Washington
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2012
- Primary completion
- 31 Dec 2013
- Completion
- 31 Dec 2013
- Last update posted
- 28 Jan 2014
- Registered enrollment
- 4
- Registry id
- NCT01677390
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.